288 related articles for article (PubMed ID: 31203242)
1. Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies.
Yamamoto H; Taguchi M; Matsuda Y; Iekushi K; Yamada T; Akizawa T
BMJ Open; 2019 Jun; 9(6):e026704. PubMed ID: 31203242
[TBL] [Abstract][Full Text] [Related]
2. Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies.
Akizawa T; Taguchi M; Matsuda Y; Iekushi K; Yamada T; Yamamoto H
BMJ Open; 2019 Jun; 9(6):e026602. PubMed ID: 31203241
[TBL] [Abstract][Full Text] [Related]
3. Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study.
Yamamoto H; Nobori K; Matsuda Y; Hayashi Y; Hayasaki T; Akizawa T
Am J Nephrol; 2021; 52(10-11):884-893. PubMed ID: 34569482
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial.
Yamamoto H; Nobori K; Matsuda Y; Hayashi Y; Hayasaki T; Akizawa T
Am J Nephrol; 2021; 52(10-11):871-883. PubMed ID: 34569489
[TBL] [Abstract][Full Text] [Related]
5. Effects of Molidustat in the Treatment of Anemia in CKD.
Macdougall IC; Akizawa T; Berns JS; Bernhardt T; Krueger T
Clin J Am Soc Nephrol; 2019 Jan; 14(1):28-39. PubMed ID: 30559105
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies.
Akizawa T; Macdougall IC; Berns JS; Bernhardt T; Staedtler G; Taguchi M; Iekushi K; Krueger T
Am J Nephrol; 2019; 49(4):271-280. PubMed ID: 30852574
[TBL] [Abstract][Full Text] [Related]
7. Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease.
Akizawa T; Macdougall IC; Berns JS; Yamamoto H; Taguchi M; Iekushi K; Bernhardt T
Nephron; 2019; 143(4):243-254. PubMed ID: 31387097
[TBL] [Abstract][Full Text] [Related]
8. Treatment satisfaction with molidustat in CKD-related anemia in non-dialysis patients: a post-hoc analysis of two clinical trials.
Yamamoto H; Yamada T; Miyazaki K; Yamashita T; Kato T; Ohara K; Nakamura Y; Akizawa T
Clin Exp Nephrol; 2023 Aug; 27(8):651-659. PubMed ID: 37095342
[TBL] [Abstract][Full Text] [Related]
9. First-in-man-proof of concept study with molidustat: a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia.
Böttcher M; Lentini S; Arens ER; Kaiser A; van der Mey D; Thuss U; Kubitza D; Wensing G
Br J Clin Pharmacol; 2018 Jul; 84(7):1557-1565. PubMed ID: 29575006
[TBL] [Abstract][Full Text] [Related]
10. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials.
Eckardt KU; Agarwal R; Farag YM; Jardine AG; Khawaja Z; Koury MJ; Luo W; Matsushita K; McCullough PA; Parfrey P; Ross G; Sarnak MJ; Vargo D; Winkelmayer WC; Chertow GM
Nephrol Dial Transplant; 2021 Nov; 36(11):2039-2048. PubMed ID: 33188693
[TBL] [Abstract][Full Text] [Related]
11. Molidustat for Japanese Patients With Renal Anemia Receiving Dialysis.
Akizawa T; Yamada T; Nobori K; Matsuda Y; Hayashi Y; Hayasaki T; Yamamoto H
Kidney Int Rep; 2021 Oct; 6(10):2604-2616. PubMed ID: 34622100
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis.
Zheng Q; Yang H; Sun L; Wei R; Fu X; Wang Y; Huang Y; Liu YN; Liu WJ
Pharmacol Res; 2020 Sep; 159():105020. PubMed ID: 32561478
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study.
Warady BA; Meyer Reigner S; Tirodkar C; Drozdz D
Am J Kidney Dis; 2023 Jun; 81(6):684-694.e1. PubMed ID: 36587890
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial.
Akizawa T; Nangaku M; Yonekawa T; Okuda N; Kawamatsu S; Onoue T; Endo Y; Hara K; Cobitz AR
Clin J Am Soc Nephrol; 2020 Aug; 15(8):1155-1165. PubMed ID: 32723804
[TBL] [Abstract][Full Text] [Related]
15. Molidustat for anemia correction in Japanese patients undergoing hemodialysis: a single-arm, phase 3 study.
Akizawa T; Nobori K; Matsuda Y; Hayashi Y; Hayasaki T; Yamamoto H
Ther Apher Dial; 2021 Dec; 25(6):917-925. PubMed ID: 33506635
[TBL] [Abstract][Full Text] [Related]
16. The ASCEND-ND trial: study design and participant characteristics.
Perkovic V; Blackorby A; Cizman B; Carroll K; Cobitz AR; Davies R; DiMino TL; Jha V; Johansen KL; Lopes RD; Kler L; Macdougall IC; McMurray JJV; Meadowcroft AM; Obrador GT; Solomon S; Taft L; Wanner C; Waikar SS; Wheeler DC; Wiecek A; Singh AK
Nephrol Dial Transplant; 2022 Oct; 37(11):2157-2170. PubMed ID: 34865143
[TBL] [Abstract][Full Text] [Related]
17. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.
Canaud B; Mingardi G; Braun J; Aljama P; Kerr PG; Locatelli F; Villa G; Van Vlem B; McMahon AW; Kerloëguen C; Beyer U;
Nephrol Dial Transplant; 2008 Nov; 23(11):3654-61. PubMed ID: 18586762
[TBL] [Abstract][Full Text] [Related]
18. Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis.
Roger SD; Kolmakova E; Fung M; Malecki R; Vinhas J; Dellanna F; Thomas M; Manamley N; Ferenczi S
Nephrology (Carlton); 2014 May; 19(5):266-74. PubMed ID: 24506498
[TBL] [Abstract][Full Text] [Related]
19. New developments in anaemia treatment - erythropoietin versus prolyl hydroxylase inhibitors?
Ryšavá R
Vnitr Lek; 2022; 68(7):438-443. PubMed ID: 36402568
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial.
Singh AK; Cizman B; Carroll K; McMurray JJV; Perkovic V; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Wiecek A; Stankus N; Strutz F; Blackorby A; Cobitz AR; Meadowcroft AM; Paul G; Ranganathan P; Sedani S; Solomon S
JAMA Intern Med; 2022 Jun; 182(6):592-602. PubMed ID: 35377393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
